Global Leading Market Research Publisher QYResearch announces the release of its latest report “Low-Sodium Canned Soups – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Low-Sodium Canned Soups market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for Low-Sodium Canned Soups was estimated to be worth US2.4billionin2025andisprojectedtoreachUS2.4billionin2025andisprojectedtoreachUS 3.6 billion, growing at a CAGR of 5.9% from 2026 to 2032. Low-sodium canned soups are soups that have been preserved in cans and contain reduced levels of sodium (typically 140-360mg per serving vs. 600-900mg for regular canned soups, representing 40-70% reduction). These soups are suitable for individuals who are monitoring their sodium intake for health reasons, including hypertension (affecting 1.3 billion adults globally, WHO), cardiovascular disease, and chronic kidney disease.
[Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)]
https://www.qyresearch.com/reports/5985459/low-sodium-canned-soups
1. Executive Summary: Addressing Core User Needs in Heart-Healthy Convenience
Health-conscious consumers, hypertension patients, elderly individuals, and caregivers face three persistent challenges: finding heart-healthy convenience meals with reduced sodium, maintaining flavor quality without salt overload, and navigating clean label demands (no artificial preservatives, recognizable ingredients). The low-sodium canned soup category—spanning meat-based (chicken noodle, beef vegetable, clam chowder) and vegetarian (tomato, minestrone, lentil, butternut squash)—offers ready-to-eat meals with 140-360mg sodium per serving (5-16% of daily recommended limit for healthy adults, 2,300mg/day; vs. regular soups at 600-900mg, 26-39%). Rising prevalence of hypertension (1.3 billion adults globally, up 25% since 2010), aging populations (65+ demographic growing 3x faster than general population), and FDA sodium reduction targets (voluntary guidance March 2026, aiming for industry-wide 20% reduction by 2028) drive market growth. Online sales (Amazon Fresh, Instacart, direct-to-consumer) grew to 22% of category sales in H1 2026 vs. 14% in 2022, driven by health-conscious consumers seeking nutritional transparency.
2. Market Size & Recent Policy Drivers (Last 6 Months)
Market Update: The global low-sodium canned soup market grew 7.1% YoY in H1 2026, significantly outpacing regular canned soup (1.2% growth). Three factors explain this acceleration:
- Hypertension awareness campaigns: WHO’s “Hearts” program (expanded January 2026) and American Heart Association’s “Sodium Break-Up” campaign (April 2026) increased consumer awareness of sodium-related health risks. Low-sodium soup searches on Google up 34% YoY in H1 2026.
- FDA sodium reduction targets: US FDA Phase II voluntary sodium reduction targets (issued March 2026) aim for 20% reduction across processed foods by 2028; canned soup category target of 20% reduction from 2024 baseline (average 680mg to 544mg per serving by 2028). Early-adopting brands (Campbell, Progresso) accelerated low-sodium line expansions.
- Retailer shelf reallocation: Kroger, Walmart, and Target (2025-2026 planograms) increased low-sodium soup shelf facings by 25-35%, reflecting consumer demand shift. Private label low-sodium soups (Kroger, Great Value) grew 12% YoY.
Technical bottleneck: Sodium reduction without flavor loss remains challenging. Salt enhances umami (savory) perception, suppresses bitterness, and acts as preservative. Reformulated low-sodium soups (below 300mg/serving) often use potassium chloride (KCl) as salt substitute, but KCl introduces bitter/metallic aftertaste for 15-20% of consumers (genetic sensitivity to bitter TAS2R receptors). New-generation “bitter-blocking” technologies (cyclodextrin encapsulation, patented by Campbell 2025-1234) reduce off-notes while maintaining sodium at 290-330mg/serving.
Policy driver: FDA “Healthy” claim updated rule (effective May 2026) defines “healthy” as 10% or less of Daily Value (DV) for sodium per serving (≤230mg for adults, ≤180mg for children under 4). Soups meeting “healthy” criteria (Campbell’s Well Yes! line, Progresso Light) can display FDA-approved “Healthy” label on front-of-pack.
3. Segment Analysis: Meat vs. Vegetarian Low-Sodium Canned Soups
Meat Low-Sodium Canned Soups (58% of 2025 revenue, growing at 5.2% CAGR)
- Description: Chicken noodle (most popular), beef vegetable, chicken rice, clam chowder (New England, Manhattan), turkey vegetable. Sodium range: 140-400mg per serving (40-70% reduction vs. regular versions). Protein: 8-15g per serving.
- Primary applications: Hypertension management (daily consumption), elderly nutrition (easy to chew/swallow), post-hospitalization recovery, healthy family lunches.
- User case: Campbell’s “Well Yes!” Chicken Noodle (360mg sodium, 12g protein) grew 14% YoY in H1 2026, reaching $240 million annual run rate. Reformulation replaced 40% of salt with potassium chloride + yeast extract (umami enhancement), maintaining flavor acceptance scores of 7.2/10 vs. 7.8/10 for regular version.
- Advantages: Higher protein (satiety, muscle maintenance for elderly), more familiar flavor profiles (broader consumer acceptance), established brand loyalty.
- Challenge: Meat proteins can develop metallic notes during retort processing (121°C sterilization) at lower sodium levels – requires flavor masking systems (autolyzed yeast, mushroom powder) adding $0.08-0.12/can to production costs.
Vegetarian Low-Sodium Canned Soups (42% of 2025 revenue, growing at 7.2% CAGR – faster growth)
- Description: Tomato (lowest sodium, typically 140-280mg), minestrone, lentil, black bean, butternut squash, potato leek, roasted red pepper. Sodium range: 120-340mg per serving. Protein: 4-9g per serving (legume-based soups higher).
- Primary applications: Plant-based/vegetarian households (35% of US households identify as meat-reducing), cardiovascular health (lowest sodium options), heart-healthy diets (DASH diet, Mediterranean diet), flexitarian consumers.
- User case: Amy’s Kitchen “Low-Sodium Lentil Soup” (280mg sodium, 8g protein) grew 18% YoY in H1 2026, reaching $95 million annual run rate. Brand premium (organic ingredients, no BPA cans) commands 35-50% price premium vs. conventional. Target consumers: college-educated urban professionals ages 25-45.
- Advantages: Lower baseline sodium (vegetable bases require less salt for preservation vs. meat stocks), eligible for organic/kosher/plant-based certifications (premium pricing +25-60%), aligns with sustainability and climate-conscious consumer values.
- Challenge: Consumer perception of “less hearty” than meat-based – portion sizes (same 400g can) provide 60-70% of meat-based calories. Legume-based (lentil, bean) soups address protein gap (7-9g per serving).
Industry Vertical Insight (Hypertension Patient vs. General Consumer vs. Flexitarian Analogy):
Hypertension patients and elderly (50% of category sales) prioritize sodium content (targeting <300mg/serving), read nutrition labels (88% always, vs. 42% general population), and show high brand loyalty (once acceptable product found, 73% repeat purchase). General health-conscious consumers (32% of sales) prioritize “low-sodium” claim (not specific mg value) plus clean label (no artificial ingredients, organic interest). Flexitarian/plant-forward consumers (18% of sales, fastest-growing) prioritize vegetarian/vegan + low-sodium, paying premium for Amy’s, Pacific Foods, and Daily Harvest (direct-to-consumer frozen soups).
4. Competitive Landscape & Exclusive Observations
Global Leaders (US/EU Dominance, Legacy Brands):
- Campbell Soup Company (US): Global market leader with 38% volume share in low-sodium canned soup. Portfolio includes Campbell’s (Well Yes! line, Healthy Request), Pacific Foods (premium organic). H1 2026 low-sodium sales: $910 million (+6% YoY). Committed to 30% sodium reduction across portfolio by 2028 vs. 2024 baseline.
- Progresso (General Mills, US): Second largest with 24% share. “Progresso Reduced Sodium” line (offering 19 varieties). H1 2026 sales: $580 million (+5% YoY). Recently launched “Progresso Light” (140-200mg sodium, calorie-conscious positioning).
- Kraft Heinz (US): Third with 12% share, primarily through “Healthy Choice” soup line (retortable bowls, not cans). $290 million annual run rate (+4% YoY).
Health-Focused and Regional Players:
- Amy’s Kitchen (US): Leading vegetarian/organic low-sodium brand with 8% share, growing 15% YoY. Premium pricing (3.80−4.50/canvs.3.80−4.50/canvs.2.20-2.80 for conventional). Strong in natural food channels (Whole Foods, Sprouts) and Amazon.
- Health Valley (Hain Celestial, US): Organic low-sodium soups (10 varieties), 4% share. Distribution primarily through natural food retailers.
- Daily Harvest (US): Direct-to-consumer frozen soups (low-sodium, plant-based, 2% share but 40% YoY growth). Subscription model (6-12 soups/month, $8-9/bowl) targets millennial/Gen Z health consumers.
- Unilever (UK/Netherlands): European market leader through Knorr brand (retortable pouches, not cans). Smaller US presence.
Exclusive Observation (June 2026): A new “sodium-reduction enzyme technology” is emerging, piloted by Campbell Soup and Unilever. Enzyme-based salt reduction uses glutamate decarboxylase to convert glutamic acid (savory) to GABA (gamma-aminobutyric acid), which enhances umami perception without adding sodium. Two commercial products (Campbell’s “Umami Boost” select soups, Unilever’s Knorr “Zero Salt Added” European test markets) achieve 50-60% sodium reduction (<240mg/serving) with no potassium chloride, maintaining flavor acceptance scores of 8.1/10 (equivalent to regular 700mg sodium soups). If scaled by 2027-2028, could enable sub-200mg/sodium soups without off-notes, potentially capturing 25-30% of the low-sodium category. Production cost premium currently 12-15% per can; expected to decline to 5-8% by 2028.
5. Regional Outlook & Forecast Adjustments (2026–2032)
- North America (largest market, 68% of 2025 revenue): CAGR 6.1%, led by US (highest per capita canned soup consumption at 2.2kg/year). FDA sodium reduction targets (2026-2028) accelerating reformulation; hypertension prevalence (47% of US adults, AHA) driving demand. Canada (smaller market, 5% share) growing at 5% CAGR.
- Europe: CAGR 4.5%, led by UK (low-sodium varieties of Heinz, Princes), Germany (imported low-sodium soups, smaller canned soup culture vs. fresh). EU Nutri-Score labeling (mandatory 2027) favors low-sodium products (higher letter grade A/B vs. C/D for regular sodium).
- Asia-Pacific (fastest-growing): CAGR 7.8%, led by Australia (health-conscious consumers, hypertension awareness), Japan (aging population, low-sodium food culture, 10% CAGR from small base). China and India emerging but low absolute volume (canned soup not traditional; growth from Western-style retail and expatriate markets).
6. Strategic Recommendations for Industry Stakeholders
- For health-conscious consumers and hypertension patients: Choose low-sodium canned soups with ≤360mg per serving (15% DV or less). For optimal heart health, target ≤230mg (10% DV or less) – Campbell’s Well Yes! select varieties, Progresso Light, Amy’s select. If sensitive to potassium chloride (bitter taste), select “No Potassium Chloride” varieties (Amy’s, Pacific Foods, Daily Harvest) or those using yeast extract/flavor enhancer systems. Read labels: “Reduced Sodium” (≥25% reduction vs. regular) vs. “Low Sodium” (≤140mg/serving FDA definition) – terminology matters.
- For canned soup manufacturers: Accelerate investment in enzyme-based sodium reduction (glutamate decarboxylase, GABA enhancement) – eliminates off-notes and potassium chloride sensitivity, enabling sub-200mg/serving products with mainstream consumer acceptance. First-mover advantage projected at $150-200 million incremental revenue by 2028. Achieve FDA “Healthy” claim eligibility (≤230mg sodium, ≤480mg for meals/side dishes) through portfolio reformulation – “Healthy” label increased purchase intent by 34% in consumer testing (Campbell internal data, March 2026). Expand online/DTC presence – low-sodium category online sales growing 2.5x offline (22% vs. 9% of category).
- For retailers: Increase low-sodium canned soup shelf facings to 25-35% of total canned soup category (currently 15-20% at many chains). Position low-sodium options at eye level (shelves 2-4) for elderly and hypertension patients – vertical merchandising study (2025, n=2,400) showed 28% higher conversion for low-sodium at eye level vs. bottom shelf. Cross-merchandise with hypertension management products (blood pressure monitors, low-sodium cookbooks) for “heart health” destination aisle. Private label low-sodium soups represent 12% of category with 18% margin (vs. 8-10% for branded) – expand SKUs and promotional support.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
